X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5573) 5573
Newsletter (196) 196
Newspaper Article (45) 45
Book Chapter (42) 42
Magazine Article (27) 27
Dissertation (12) 12
Publication (6) 6
Conference Proceeding (4) 4
Book Review (1) 1
Government Document (1) 1
Streaming Video (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4118) 4118
science & technology (3668) 3668
life sciences & biomedicine (3482) 3482
hiv infections - drug therapy (2656) 2656
ritonavir (2513) 2513
male (2461) 2461
female (2177) 2177
adult (2008) 2008
ritonavir - therapeutic use (1924) 1924
infectious diseases (1705) 1705
middle aged (1488) 1488
ritonavir - administration & dosage (1427) 1427
pharmacology & pharmacy (1405) 1405
drug therapy, combination (1359) 1359
lopinavir (1331) 1331
hiv protease inhibitors - therapeutic use (1276) 1276
hiv (1194) 1194
aids/hiv (1049) 1049
ritonavir - adverse effects (1030) 1030
anti-hiv agents - therapeutic use (953) 953
immunology (927) 927
virology (813) 813
hiv protease inhibitors - administration & dosage (810) 810
protease inhibitors (808) 808
drug therapy (780) 780
hiv infections - virology (779) 779
human immunodeficiency virus--hiv (771) 771
ritonavir - pharmacology (769) 769
treatment outcome (763) 763
viral load (761) 761
drug interactions (748) 748
hiv protease inhibitors - adverse effects (737) 737
ritonavir - pharmacokinetics (733) 733
antiviral agents (731) 731
antiretroviral drugs (652) 652
anti-hiv agents - administration & dosage (650) 650
hiv-1 - drug effects (633) 633
microbiology (583) 583
hiv infection (562) 562
hiv protease inhibitors - pharmacology (559) 559
cd4 lymphocyte count (556) 556
hiv protease inhibitors - pharmacokinetics (541) 541
antiretroviral therapy (481) 481
anti-hiv agents - adverse effects (473) 473
drug combinations (465) 465
darunavir (448) 448
research (448) 448
aged (433) 433
pharmacokinetics (428) 428
hiv-1 (426) 426
adolescent (411) 411
health aspects (409) 409
antiretroviral therapy, highly active (407) 407
pyrimidinones - therapeutic use (406) 406
drug administration schedule (396) 396
animals (382) 382
atazanavir sulfate (382) 382
rna, viral - blood (381) 381
highly active antiretroviral therapy (380) 380
young adult (372) 372
patients (371) 371
dosage and administration (356) 356
proteases (356) 356
reverse transcriptase inhibitors - therapeutic use (352) 352
virus diseases (351) 351
hiv-1 - genetics (349) 349
analysis (348) 348
aids (345) 345
sulfonamides - therapeutic use (345) 345
anti-hiv agents - pharmacokinetics (339) 339
human immunodeficiency virus (339) 339
clinical trials (333) 333
abridged index medicus (327) 327
pharmacology (324) 324
tenofovir (324) 324
hiv infections - complications (319) 319
hiv infections - immunology (316) 316
hiv infections - blood (313) 313
care and treatment (306) 306
sulfonamides - administration & dosage (298) 298
pyrimidinones - administration & dosage (296) 296
ritonavir - blood (293) 293
prospective studies (290) 290
pyridines - therapeutic use (285) 285
lopinavir - therapeutic use (282) 282
genotype (272) 272
drugs (263) 263
saquinavir - therapeutic use (258) 258
retrospective studies (256) 256
viruses (255) 255
area under curve (252) 252
saquinavir (252) 252
hiv protease inhibitors - blood (249) 249
risk factors (247) 247
antiviral agents - therapeutic use (242) 242
hepatitis c (241) 241
dose-response relationship, drug (240) 240
infections (238) 238
mutation (238) 238
anti-hiv agents - pharmacology (237) 237
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5675) 5675
Spanish (118) 118
French (49) 49
German (44) 44
Portuguese (26) 26
Japanese (23) 23
Chinese (16) 16
Russian (13) 13
Czech (5) 5
Italian (4) 4
Korean (4) 4
Dutch (3) 3
Hungarian (3) 3
Danish (2) 2
Hebrew (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9568, pp. 1169 - 1178
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2014, Volume 370, Issue 17, pp. 1594 - 1603
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2014, Volume 370, Issue 17, pp. 1604 - 1614
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
Background & Aims The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside... 
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 03/2020, Volume 382, Issue 19, pp. 1787 - 1799
Investigators in China report the results of an open-label, randomized clinical trial of lopinavir–ritonavir for the treatment of Covid-19 in 199 infected... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Pandemics | Clinical Laboratory Techniques | Coronavirus Infections - drug therapy | Humans | Middle Aged | Pneumonia, Viral - drug therapy | Male | Coronavirus Infections - mortality | Viral Load | Ritonavir - adverse effects | Treatment Failure | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Betacoronavirus - isolation & purification | Hospital Mortality | Time-to-Treatment | Antiviral Agents - therapeutic use | Coronavirus Infections - diagnosis | Proportional Hazards Models | Reverse Transcriptase Polymerase Chain Reaction | Patient Acuity | Coronavirus Infections - virology | Antiviral Agents - adverse effects | Intention to Treat Analysis | Lopinavir - therapeutic use | Aged | Pneumonia, Viral - mortality | Cytochrome P-450 CYP3A Inhibitors - adverse effects | Cytochrome P-450 CYP3A Inhibitors - therapeutic use | Betacoronavirus - genetics | Pneumonia, Viral - virology | Lopinavir - adverse effects | Drug therapy, Combination | Ritonavir | Lopinavir | Testing | Pneumonia | Oxygen | Laboratories | Clinical trials | Coronaviruses | Ribonucleic acid--RNA | Patients | Middle East respiratory syndrome | Clinical outcomes | Severe acute respiratory syndrome coronavirus 2 | COVID-19 | Human immunodeficiency virus--HIV | Influenza | Respiratory diseases | Index Medicus | Abridged Index Medicus
Journal Article
Gastroenterology, ISSN 0016-5085, 2015, Volume 149, Issue 4, pp. 971 - 980.e1
Background & Aims Interferon-free treatment options are rapidly evolving for patients with chronic hepatitis C virus (HCV) genotype 1b (GT1b) infection with... 
Gastroenterology and Hepatology | Direct-Acting Antivirals | Interferon-Free/Ribavirin-Free | HCV Genotype 1b | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Recurrence | Anilides - therapeutic use | United States | Anilides - adverse effects | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Male | Carbamates - administration & dosage | Hepatitis C, Chronic - complications | Enzyme Inhibitors - administration & dosage | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Female | Drug Therapy, Combination | Enzyme Inhibitors - adverse effects | Hepacivirus - drug effects | Liver Cirrhosis - drug therapy | Liver Cirrhosis - diagnosis | Ritonavir - administration & dosage | Administration, Oral | Antiviral Agents - therapeutic use | Europe | Carrier Proteins - antagonists & inhibitors | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Enzyme Inhibitors - therapeutic use | Remission Induction | Macrocyclic Compounds - therapeutic use | Hepacivirus - enzymology | Liver Cirrhosis - virology | Anilides - administration & dosage | Antiviral Agents - adverse effects | Carbamates - adverse effects | Aged | Macrocyclic Compounds - administration & dosage | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Virus diseases | Medical research | Proteases | Ritonavir | Analysis | Liver | Medicine, Experimental | Biological response modifiers | Hepatitis C virus | Health aspects | Gangliosides | Liver cirrhosis | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Clinical infectious diseases, ISSN 1058-4838, 06/2015, Volume 60, Issue 12, pp. 1842 - 1851
Journal Article